RT Journal Article
SR Electronic
T1 Decoding Clinical Biomarker Space of COVID-19: Exploring Matrix Factorization-based Feature Selection Methods
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.07.21259699
DO 10.1101/2021.07.07.21259699
A1 Saberi-Movahed, Farshad
A1 Mohammadifard, Mahyar
A1 Mehrpooya, Adel
A1 Rezaei-Ravari, Mohammad
A1 Berahmand, Kamal
A1 Rostami, Mehrdad
A1 Karami, Saeed
A1 Najafzadeh, Mohammad
A1 Hajinezhad, Davood
A1 Jamshidi, Mina
A1 Abedi, Farshid
A1 Mohammadifard, Mahtab
A1 Farbod, Elnaz
A1 Safavi, Farinaz
A1 Dorvash, Mohammadreza
A1 Vahedi, Shahrzad
A1 Eftekhari, Mahdi
A1 Saberi-Movahed, Farid
A1 Tavassoly, Iman
YR 2021
UL http://medrxiv.org/content/early/2021/07/09/2021.07.07.21259699.abstract
AB One of the most critical challenges in managing complex diseases like COVID-19 is to establish an intelligent triage system that can optimize the clinical decision-making at the time of a global pandemic. The clinical presentation and patients’ characteristics are usually utilized to identify those patients who need more critical care. However, the clinical evidence shows an unmet need to determine more accurate and optimal clinical biomarkers to triage patients under a condition like the COVID-19 crisis. Here we have presented a machine learning approach to find a group of clinical indicators from the blood tests of a set of COVID-19 patients that are predictive of poor prognosis and morbidity. Our approach consists of two interconnected schemes: Feature Selection and Prognosis Classification. The former is based on different Matrix Factorization (MF)-based methods, and the latter is performed using Random Forest algorithm. Our model reveals that Arterial Blood Gas (ABG) O2 Saturation and C-Reactive Protein (CRP) are the most important clinical biomarkers determining the poor prognosis in these patients. Our approach paves the path of building quantitative and optimized clinical management systems for COVID-19 and similar diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAcknowledgments I.T. contributed to this paper at the Cellular Energetics Program of the Kavli Institute for Theoretical Physics, supported in part by the National Science Foundation Grant NSF PHY-1748958, NIH Grant R25GM067110, and the Gordon and Betty Moore Founda- tion Grant 2919.02. This work was partly supported by the Intramural Research Pro- gram of the National Institute of Neurological Disorder and Stroke/ National Institutes of Health (Grant NS003031) (to F.S.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of Birjand University of Medical Sciences in Iran approved this study. Anonymised clinical data of all patients with COVID-19 who had been admitted in clinical centers of Birjand University of Medical Sciences during the mentioned time were used according to the Institutional Review Board (IRB) of Birjand University of Medical Sciences permission.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesParticipants of this study did not agree for their data to be shared publicly, so supporting data is not available.(ALT)Alanine Aminotransferase(ABG)Arterial Blood Gas(AI)Artificial Intelligence(AST)Aspartate Aminotransferase(CNS)Central Nervous System(ACC)Classification/Clustering Accuracy(CBC)Complete Blood Count(CNMF)Convex NMF(COVID-19)Coronavirus Disease 2019(CV)Cross-Validation(CRP)C-Reactive Protein(DLBCL)Diffuse large B-cell lymphoma(FN)False Negative(False Positive)False Positive(FS)Feature Selection(HSIC)Hilbert Schmidt Independence Criterion(INR)International Normalized Ratio(Isomap)Isometric Feature Mapping(LDA)Linear Discriminant Analysis(LPP)Locality Preserving Projection(LLE)Locally Linear Embedding(ML)Machine Learning(MF)Matrix Factorization(MFFS)Matrix Factorization Feature Selection(MPMR)Maximum Projection and Minimum Redundancy(MCFS)Multi-Cluster Feature Selection(NPV)Negative Predictive Value(NPE)Neighborhood Preserving Embedding(NMF)Non-Negative Matrix Factorization(NMI)Normalized Mutual Information(ONMF)Orthogonal NMF(PMH)Past Medical History(PTT)Partial Thromboplastin Time(PCR)Polymerase Chain Reaction(PPV)Positive Predictive Value(PCA)Principal Components Analysis(PMF)Probabilistic Matrix Factorization(RMFFS)Regularized Matrix Factorization Feature Selection(SNMF)Semi NMF(SVD)Singular Value Decomposition(SRBCT)Small Round Blue Cell TumorsSLSDR)Sparse and Low-redundant Subspace learning-based Dual-graph Regularized Robust(SGFS)Subspace Learning-Based Graph Regularized Feature Selection(TN)True Negative(TNR)True Negative Rate(TP)True Positive(TPR)True Positive Rate(WBC)White Blood Cells